IP Library Granted Patent US 10,953,445
Granted Patent B2
US 10,953,445 · App. 15/790,100 · Granted Mar 23, 2021

Single procedure indicators

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,953,445
App. No.
15/790,100
Granted
Mar 23, 2021
Kind
B2
Abstract

Disclosed herein are single use indicators and methods for employing the same. Such indicators and their uses are directed towards identifying the discharge status of single procedure devices, which are typically, but not limited to, medical devices.

Claims (18)

1. A method for determining the discharge status of a single procedure device, comprising:

(a) providing the device, wherein the device includes at least one indicator region configured to transition from an unmodified state to a modified state in response to an exposure wherein said indicator region comprises a biocompatible composition including one or more superabsorbent polymers possessing a swelling capacity range of about 30-500 fold the volume of the one or more superabsorbent polymers prior to being subject to exposure;

(b) subjecting the device to the exposure after the single procedure has been performed using the device;

(c) assessing the transition state of the at least one indicator region, wherein the modified state of the at least one indicator region irreversibly identifies by swelling of said one or more superabsorbent polymers that the device has been subjected to the exposure after the single procedure; and

(d) determining the discharge status of the device based on the transition state assessment of the at least one indicator region, wherein the device is affirmatively discharged when the at least one indicator region is in the modified state.

2. The method of claim 1 , further comprising one or more of:

(a) labelling the affirmatively discharged device as end of-use;

(b) segregating the affirmatively discharged device from other single procedure devices that have not been affirmatively discharged; and

(c) disposing of the affirmatively discharged device.

3. The method of claim 1 , wherein the exposure comprises the device including the at least one indicator region to (i) the presence of water, or (ii) one or more steam sterilization cycles, or both.

4. The method of claim 1 , wherein the device is a single-use medical device comprising a proximal end and a distal end, and wherein the at least one indicator region is located at or about the proximal end of the medical device.

5. The method of claim 1 , wherein the biocompatible composition further comprises one or more binders, one or more additives, and a solvent, and combinations thereof.

6. The method of claim 5 , wherein the one or more superabsorbent polymer is present at a range of about 30-90 by weight percentage in the biocompatible composition.

7. The method of claim 6 , wherein the one or more superabsorbent polymers are selected from the group consisting of polyacrylates, polyacrylamides, polyacrylamide copolymers, polyacrylic acid, sodium polyacrylate, potassium polyacrylate, lithium polyacrylate, ammonium polyacrylate, ethylene maleic anhydride copolymer, carboxymethylcellulose, polyvinyl alcohol copolymers, polyethyleneoxide, and copolymers of polyacrylonitrile, and combinations thereof.

8. The method of claim 7 , wherein the one or more superabsorbent polymers is sodium polyacrylate, and wherein the sodium polyacrylate possesses a degree of ionization ranging from about 30-100 percent.

9. The method of claim 5 , wherein the one or more binders are present at a range of about 10-70 by weight percentage in the biocompatible composition, and wherein the one or more binders are selected from the group consisting of alkyds, acrylics, vinyl-acrylics, polyurethanes, polyesters, melamine, epoxies, silanes, siloxanes, and oils, and combinations thereof.

10. The method of claim 5 , wherein the one or more additives are present at a range of about 0.1-10 by weight percentage in the biocompatible composition, and wherein the one or more additives are selected from the group consisting of clays, kaolin, limestone, silicate compounds, and quartz, and combinations thereof.

11. The method of claim 5 , herein the one or more solvents are present at a range of about 0.1-60 by weight percentage in the biocompatible composition, and wherein the one or more solvents are selected from the group consisting of xylene, toluene, alcohols, and ketones, and combinations thereof.

Assignments (9)
SECOND LIEN PATENT SECURITY AGREEMENT Recorded Nov 1, 2024
From: VIANT AS&O HOLDINGS, LLC (F/K/A BANDERA ACQUISITION, LLC)
To: HPS INVESTMENT PARTNERS, LLC, AS COLLATERAL AGENT
Reel/Frame 069288/0915 →
RELEASE OF SECURITY INTEREST Recorded Oct 31, 2024
From: ROYAL BANK OF CANADA
To: VIANT AS&O HOLDINGS, LLC
Reel/Frame 069286/0564 →
SECURITY INTEREST Recorded Oct 31, 2024
From: VIANT AS&O HOLDINGS, LLC
To: UBS AG, STAMFORD BRANCH
Reel/Frame 069287/0709 →
RELEASE OF SECURITY INTEREST Recorded Oct 30, 2024
From: ROYAL BANK OF CANADA
To: VIANT AS&O HOLDINGS, LLC
Reel/Frame 069276/0081 →
CHANGE OF NAME Recorded Oct 12, 2018
From: BANDERA ACQUISITION, LLC
To: VIANT AS&O HOLDINGS, LLC
Reel/Frame 047221/0275 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 26, 2018
From: GREATBATCH LTD.
To: BANDERA ACQUISITION, LLC
Reel/Frame 047224/0012 →
SECURITY INTEREST Recorded Jul 3, 2018
From: BANDERA ACQUISITION, LLC
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 046472/0475 →
SECURITY INTEREST Recorded Jul 3, 2018
From: BANDERA ACQUISITION, LLC
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 046472/0545 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2017
From: DAS, BISWA P.; SHAH, ASHISH
To: GREATBATCH LTD.
Reel/Frame 043919/0416 →